SUMMARY
The authors devised an efficient method for ticagrelor removal from blood using sorbent hemadsorption.
Ticagrelor removal was measured in 2 sets of in vitro experiments. The first set was a first-pass experiment using bovine serum albumin (BSA) solution pre-incubated with ticagrelor, whereas the second set, performed in a recirculating manner, used human blood mixed with ticagrelor. Removal of ticagrelor from BSA solution reached values >99%. The peak removal rate was 99% and 94% from whole blood and 99.99% and 90% from plasma during 10 h and 3 to 4 h of recirculating experiments, respectively.
In conclusion, hemadsorption robustly removes ticagrelor from BSA solution and human blood samples. The rate of major bleeding in ticagrelor as well as clopidogrel-treated patients in the PLATO trial was similar: 11.6% and 11.2%, and 81% among patients undergoing CABG (1, 3) . Platelet transfusion is not a complete solution due to the remaining amount of drug present in the circulation that can redistribute and inhibit the new platelets. Because ticagrelor is reversibly bound to P2Y 12 and plasma proteins, removing the drug from the systemic circulation by means of sorbent technology could reverse the druginduced antiplatelet effect.
The bleeding rate with ticagrelor is not known for types of surgery other than cardiothoracic. Two case reports indicate spontaneous bleeding with ticagrelor (abdomen and lung) (4, 5) that required surgery, and a relatively small study showed increased rate of bleeding with abdominal surgery needing transfusion with a different class of antiplatelet medication-clopidogrel, a thienopyridine (6) . A similar bleeding risk profile was documented during CABG between ticagrelor and clopidogrel (1) .
As a consequence, current guidelines require at least 5 days' ticagrelor discontinuation prior to elective surgeries of any type-thoracic or abdominal-in a similar manner with clopidogrel (7).
Dialysis is not a viable removal route, because 99.8% of ticagrelor is protein-bound. Other P2Y 12 receptor antagonists (clopidogrel and prasugrel) have similar albumin-biding affinities (98%) (8) , whereas aspirin has a lower affinity to proteins (58%) (9) .
Our group has demonstrated that various sorbent beads (e.g., CytoSorb, Cytosorbents, Monmouth Junction, New Jersey; Porapak Q 50-80 mesh, Supelco, Bellefonte Pennsylvania) can adsorb iodinated contrast molecules such as iodixanol and iohexol with a peak removal rate of 95%, as well as dabigatran (10, 11) . These molecules contain several hydroxyl groups linked to nitrogen atoms and central hydrophobic structures (benzene rings). In a similar way, the ticagrelor molecule contains hydroxyl and nitrogen radicals attached to a central hydrophobic ring, and it is possibly able to link through similar bonds with the styrene copolymers. We hypothesize that ticagrelor can be adsorbed by CytoSorb and Porapak Q 50-80 mesh sorbent beads from albumin solution and human blood, creating the premises of a unifying method able to remove molecules representative of 3 classes frequently used in cardiology-antiplatelet, anticoagulant, and radiocontrast agents.
METHODS
Porapak Q 50-80 mesh and CytoSorb (graciously donated by Cytosorbents) are styrene copolymer with bead diameters of 125 to 149 and 425 to 1,000 mm and surface area of 550 and 850 m 2 /g, respectively. In the current study, both sorbents were separately used to remove ticagrelor from bovine serum albumin (BSA) solution in normal saline, whereas CytoSorb was used also to remove the drug from human blood samples. 
Angheloiu et al. Experimental setup for ticagrelor removal from BSA solution (A) and human blood (B). BSA, bovine serum albumin.
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Ticagrelor Removal M o d e l 1 . In this model, 250 ml blood from BioreclamationIVT was mixed with 9.2 mg of ticagrelor and passed at a velocity of 9 ml/min through 14 10-ml columns housing a total of 59 g of CytoSorb and mounted in series for a total of 10 h.
M o d e l 2 . In this model, 500 ml of blood from BioreclamationIVT was mixed with 18.1 mg of ticagrelor and passed at a velocity of 17 ml/min through a column housing 300 ml of CytoSorb (158 g) for a total of 10 h. Abbreviation as in Figure 1 . C and shipped in dry ice.
TICAGRELOR ASSAY. Ticagrelor concentration in BSA solution, plasma and whole blood was measured using a liquid chromatography technique with tandem mass spectrometric detection (13) . All aliquots belonging to each particular experiment were performed in same assay batch. To 500 ml of each sample, 1 ml acetonitrile was added, vortexed at room temperature for 10 min, and centrifuged at 2,000g for 15 min at 20 C. The supernatant was evaporated to dryness then redissolved in 1 ml of 50% methanol containing 5 mmol/l ammonium formate and 100 fmol/ml verapamil for analysis.
A calibration curve was measured for ticagrelor using synthetic standard from 4.6 fmol/ml to 4.6 nmol/ml. Each calibration point contained 100 fmol/ml of verapamil as an internal standard. (Torrance, California) 2.1 Â 50 mm, 1.8-mm particle size was used for chromatography.
All computations regarding ticagrelor removal were performed using liquid chromatography with tandem mass spectroscopy assay-measured concentrations. Measurements of concentrations in aliquots from same experiments were performed in same Removal rate of ticagrelor from whole human blood purchased from a blood bank during a recirculating experiment using CytoSorb in 2 models, on 14 10-ml columns mounted in series (model 1) (A) or 1 300-ml column (model 2) (B).
FIGURE 4 Removal Rate of Ticagrelor From Whole Human Blood and Plasma
Removal rate of ticagrelor from whole human blood (A) and plasma (B) freshly (<60-min interval until being used) collected during model 3
of the blood recirculating experiment using CytoSorb.
Angheloiu et al. BSA concentration showed an average 9.6% drop for the entire range of columns' volumes.
BLOOD EXPERIMENTS. Because the study reached close to 100% ticagrelor removal in BSA solution, we pursued a second phase looking at ticagrelor removal in human blood.
In a manner similar to the BSA experiments, ticagrelor whole blood concentration was reduced by a maximum of 96% in model 1 and 99% in model 2 using CytoSorb ( Figure 3 ) at 10 h of a recirculating experiment. We employed 2 different structures of columns (a series of 10-ml columns vs. a single 300-ml column), mass of sorbents (59 g vs. 158 g) and filtration velocities (3 ml/min vs. 17 ml/min). At 3 and 7 h, the removal rate was 90% and 94%, respectively, in model 1, and flat 99% in model 2.
The largest column (300 ml), used in model 2, removed >99% of ticagrelor from whole blood in the first 3 h ( Figure 3B ).
At baseline, the average mixed whole blood ticagrelor concentration in the 3 models was 70 AE providing an enhanced adenosine response (15,16).
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Ticagrelor Removal
In this in vitro study, we used 2 sorbents to demonstrate efficient removal of ticagrelor in albumin solution as well as from human blood.
REMOVAL EFFICIENCY. B o v i n e s e r u m a l b u m i n e x p e r i m e n t s . We succeeded in removing ticagrelor using both CytoSorb and Porapak Q 50-80 mesh from BSA solution. As expected adsorption was seemingly better using higher masses of sorbent (Figures 2A   and 2B ). Ticagrelor is 99.8% bound to albumin (17) , and the fact that the peak removal rate for the 2 sorbents was 99% and 100%, respectively (Figure 2 ), suggests that both sorbents were able to remove ticagrelor from the albumin molecules.
Varying the concentrations of albumin (4% vs. ( Figures 4A and 3, respectively) . At the same time,
exposing the ticagrelor at 5 h in mid-experiment to a fresh volume of sorbent did not change the result (Figures 3 and 4A, respectively) .
CLINICAL SIGNIFICANCE. In patients, the mean maximum and minimum plasma concentration in blood following 4 weeks of treatment (90 mg twice a day) is 1.5 mmol/l (770 ng/ml) and 0.4 mmol/l (227 ng/ml), respectively (12) . A high plasma concentration of ticagrelor (67.36 mmol/l) was used specifically to explore the concept of ticagrelor removal in vitro, allowing us to demonstrate an impressive removal efficiency. At the same time, we were able to Comparison of ticagrelor (A) and main metabolite AR-C124910XX (B) structures.
assess the amount of sorbent needed to remove ticagrelor from circulation in a clinical loading scenario.
After a loading dose (180 mg), the clinical mean maximal concentration is 931 ng/ml (1.78 mmol/l),
hence the total amount of ticagrelor in the human body is 82 mg for a distribution volume of 88 l in an average patient (12) . We were able in model 2 of blood experiments to remove 18 mg of ticagrelor using a 300-ml column containing 158 g of sorbent. Subsequently approximately 5 300-ml columns with a total sorbent mass of 790 g will eventually be needed to remove 82 mg of drug in a clinical experiment.
Our method was able to reduce ticagrelor levels in plasma, extracted from samples of blood pre- This study had to answer a fundamental initial question: do sorbents bind ticagrelor molecules? Sorbents do not necessarily bind drug molecules in a universal fashion, with some drugs having high affinity for sorbent beads and others demonstrating no interaction at all. Our group showed an excellent capacity of sorbents to bind and remove ticagrelor (>99% in plasma and whole blood as well as BSA). The free ticagrelor fraction is part of the plasma-soluble drug; therefore, we assume that sorbents may have a similar effect on the free plasma ticagrelor component and finally on the platelet aggregability recovery (19) . To fully prove our method's clinical effect, one will need in the future results of platelet aggregability tests to demonstrate aggregability recovery after ticagrelor removal, which
was not the present study's objective. At the same time, experiments comparing the sorbent versus monoclonal antibody approaches for ticagrelor removal or reversal can be considered for future studies (19) .
A specific monoclonal antibody reversal agent for ticagrelor has been identified and its pharmacology has been characterized in vitro as well as in vivo (19) . Hence, in our setup, the blood is circulated directly through the sorbent (in our text and Träger et al. [22] ), avoiding in this way the costs incurred by plasma separation in plasmapheresis. The circulating system is already in place in the potential case of removing ticagrelor during CABG, represented by the cardiopulmonary bypass machine.
Interestingly the drop in albumin was rather minor (<10%) in comparison to an almost complete removal of ticagrelor. Importantly albumin interacts mostly
Angheloiu et al. These particular objectives were not goals of this study. 
